Last $113.10 USD
Change Today +1.09 / 0.97%
Volume 1.2M
KMB On Other Exchanges
Symbol
Exchange
New York
Stuttgart
New York
As of 8:04 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

kimberly-clark corp (KMB) Snapshot

Open
$112.66
Previous Close
$112.01
Day High
$113.44
Day Low
$112.36
52 Week High
07/16/14 - $114.45
52 Week Low
12/17/13 - $102.53
Market Cap
42.1B
Average Volume 10 Days
1.9M
EPS TTM
$5.55
Shares Outstanding
372.5M
EX-Date
09/3/14
P/E TM
20.4x
Dividend
$3.36
Dividend Yield
2.94%
Current Stock Chart for KIMBERLY-CLARK CORP (KMB)

kimberly-clark corp (KMB) Details

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care, consumer tissue, and health care products worldwide. It operates through four segments: Personal Care, Consumer Tissue, K-C Professional, and Health Care. The Personal Care segment offers disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Kotex, U by Kotex, Intimus, Depend, Plenitud, and Poise names. The Consumer Tissue segment provides facial and bathroom tissue, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, and Neve names. The K-C Professional segment offers apparel, wipers, soaps, sanitizers, tissues, and towels under the Kleenex, Scott, WypAll, Kimtech, and Jackson Safety names. The Health Care segment provides surgical and infection prevention products for the operating room; and a portfolio of medical devices focused on pain management, respiratory, and digestive health under the Kimberly-Clark and ON-Q brands. The company sells its products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce. It also sells products for away-from-home use through distributors and directly to manufacturing, lodging, office building, food service, health care establishments, and public facilities. The company was founded in 1872 and is headquartered in Dallas, Texas.

57,000 Employees
Last Reported Date: 02/14/14
Founded in 1872

kimberly-clark corp (KMB) Top Compensated Officers

Executive Chairman, Chief Executive Officer, ...
Total Annual Compensation: $1.3M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $781.3K
President of Global Health Care
Total Annual Compensation: $780.0K
Group President of Kimberly-Clark North Ameri...
Total Annual Compensation: $657.5K
President of Global Brands & Innovation
Total Annual Compensation: $580.0K
Compensation as of Fiscal Year 2013.

kimberly-clark corp (KMB) Key Developments

Kimberly-Clark Australia to Invest $20 Million in its Tissue Manufacturing Plant in Millicent in South Australia

Kimberly-Clark Australia announced that it will invest $20 million in its tissue manufacturing plant in Millicent in South Australia has been welcomed by the peak national body for the forest, wood and paper products industry.

Kimberly-Clark Corp. Plans to Eliminate Up to 1,300 Jobs as Part of Restructuring Efforts

Kimberly-Clark Corp. plans to eliminate up to 1,300 jobs as part of restructuring efforts aimed at reducing costs and making its business more efficient. The company announced that it anticipates restructuring costs between $130 million and $160 million, after taxes. The company - whose brands include Kleenex and Huggies - foresees between $120 million and $140 million in savings by the end of 2017. The restructuring is expected to be completed by the end of 2016.

Kimberly-Clark Corporation Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for 2014

Kimberly-Clark Corporation announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net sales of $5,442 million against $5,262 million a year ago. Operating profit was $907 million against $807 million a year ago. Income before income taxes and equity interests was $841 million against $740 million a year ago. Net income attributable to the company was $562 million against $546 million a year ago. Diluted income per share was $1.50 against $1.42 a year ago. Cash provided by operations was $976 million against $912 million a year ago. Capital spending was $291 million against $203 million a year ago. For the nine months, the company reported net sales of $16,063 million against $15,847 million a year ago. Operating profit was $2,494 million against $2,386 million a year ago. Income before income taxes and equity interests was $2,293 million against $2,191 million a year ago. Net income attributable to the company was $1,609 million against $1,603 million a year ago. Diluted income per share was $4.25 against $4.13 a year ago. Cash provided by operations was $2,255 million against $2,095 million a year ago. Capital spending was $730 million against $697 million a year ago. Non-GAAP net income attributable to the company was $1,734 million against $1,681 million a year ago. Non-GAAP diluted income per share was $4.58 against $4.33 a year ago. As adjusted earnings from continuing operations were $1,575 million against $1,531 million a year ago. Adjusted earnings from continuing operations per share were $4.16 against $3.95 a year ago. Adjusted earnings per share in 2014 are expected to be $5.93 to $6.03 and assume the health care spin-off occurs at the end of October 2014. The company's previous target was $6.00 to $6.15 per share and assumed a full year of results for the health care business. The updated guidance includes a 10% share impact from the spin-off of the last two months of 2014 health care earnings. After the spin-off, historical results for health care will be reported as earnings from discontinued operations. The company's outlook for 2014 adjusted earnings per share of $5.93 to $6.03 includes $5.46 to $5.56 in adjusted earnings from continuing operations and $0.47 of adjusted earnings from discontinued operations. Diluted net income attributable to the company expected to be $5.28 to $5.44 per share. Effective tax rate expected to be 32.0% to 33.7%. Adjusted effective tax rate expected to be 31.0% to 32.5%. Full-year capital spending is expected to be toward the low end of the company's target range of $1.0 to $1.2 billion.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KMB:US $113.10 USD +1.09

KMB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $69.83 USD +0.73
Covidien PLC $89.64 USD +1.19
Danaher Corp $77.96 USD +0.60
Ecolab Inc $112.72 USD +0.16
Koninklijke Philips NV €21.23 EUR +0.09
View Industry Companies
 

Industry Analysis

KMB

Industry Average

Valuation KMB Industry Range
Price/Earnings 20.0x
Price/Sales 2.0x
Price/Book 9.9x
Price/Cash Flow 19.6x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KIMBERLY-CLARK CORP, please visit www.kimberly-clark.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.